A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

20021,654 citationsJournal Articlebronze Open Access

Authors

Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.

Good health and well-being

Published in: JNCI Journal of the National Cancer Institute

Volume 94, Issue 19, pp. 1458-1468

Field-Weighted Citation Impact: 41.48